Algorae Pharmaceuticals Ltd Named Launch Partner in Sovereign AI Initiative

Algorae becomes healthcare launch partner for NVIDIA-backed sovereign AI initiative

Algorae Pharmaceuticals (ASX: 1AI) has been named a foundation participant and the healthcare and life sciences launch partner in the new Sovereign AI Infrastructure (SAII) initiative, led by AgenticScale.ai and built on NVIDIA-accelerated technology.

SAII was formally launched on 26 June 2026 in Melbourne, with Algorae’s appointment confirmed in an announcement dated 29 June 2026. As launch partner, the company intends to be among the first organisations to apply SAII’s secure, sovereign AI infrastructure, positioning healthcare and life sciences as a flagship use case for the initiative.

What the SAII partnership means for Algorae

As launch partner, Algorae intends to apply SAII’s “secure, sovereign AI infrastructure” to its AI-enabled drug discovery and development. The company is not approaching this from a standing start. It brings an established capability through AlgoraeOS, its proprietary AI drug discovery platform, which it intends to run within SAII’s governed environments.

Separately, Algorae has engaged AgenticScale.ai under a distinct staged programme of work. This second arrangement is aimed at developing AI and automation capabilities across both its drug discovery and its commercial pharmaceutical operations, and is separate from the SAII launch partnership itself.

No dollar figures, valuations, or share prices have been disclosed for either arrangement. The company has stated that its participation in SAII is non-binding and being finalised, that it is not responsible for the initiative’s overall delivery or funding, and that it does not expect to incur material capital expenditure.

David Hainsworth, Executive Chairman, Algorae

“Access to secure, sovereign infrastructure is the natural next step in applying that capability responsibly and effectively. As launch partner, Algorae is helping shape how AI is applied in healthcare, where it can make a real difference to patients.”

Understanding sovereign AI infrastructure

Sovereign AI infrastructure refers to secure, governed environments where AI systems can be built, tested, validated and deployed, with data and compliance kept under local or organisational control. The idea is to give organisations greater oversight of how their AI models are trained and how their data is handled.

This matters for highly regulated fields such as drug discovery, where AI can be developed and validated in governed, auditable environments. For investors, this positions Algorae’s discovery work within a trusted framework at a time when regulators are increasingly scrutinising the use of AI in healthcare.

SAII is an Australian initiative focused on the development of secure sovereign AI environments that support:

• Private model training

• AI assurance and benchmarking

• Adversarial testing and red-teaming

• AI governance and compliance

• Agentic AI validation

• Secure AI deployment

Richard Harding, Chief Technology Officer, SAII

“The next phase of artificial intelligence will be defined by infrastructure, governance and trust.”

Algorae’s existing AI platform and dual-track strategy

AlgoraeOS is a proprietary AI platform that applies machine learning and deep neural networks to predict synergistic drug combinations. It was developed in collaboration with the UNSW AI Institute, with support from CSIRO Data61, and its predictions have been independently validated by the Peter MacCallum Cancer Centre.

The platform underpins a growing pipeline of AI-generated drug-combination candidates across oncology, neurodegenerative and other complex diseases.

Algorae pursues a dual-track strategy. Alongside its AI-driven discovery work, it commercialises specialty and generic medicines through its wholly owned division, AlgoraeRx, bringing products to market across Australia and New Zealand under distribution and supply partnerships. This builds a revenue base that complements its longer-term discovery pipeline.

The table below summarises the key elements of Algorae’s positioning and why each may be relevant for investors.

What comes next

The SAII partnership is best understood as positioning rather than committed delivery. Algorae has reiterated that its participation is being finalised and remains non-binding, with no material capital expenditure expected.

The broader SAII vision extends well beyond Algorae. AgenticScale.ai has outlined proposed facility locations under consideration, including the Melbourne headquarters, Western Australia, Exmouth, Texas (Austin and San Antonio), and Europe, with Ireland and Estonia under evaluation. These locations relate to SAII broadly and not to any Algorae arrangement, and the “one of the world’s first sovereign AI training and validation networks” language applies to the SAII network, not to Algorae itself.

For investors, the development reflects Algorae deepening its application of AI across both discovery and commercial operations as it scales. The dual-track strategy continues to combine longer-term pipeline potential with a near-term commercial revenue base, now supported by access to sovereign infrastructure intended for highly regulated environments.

Ready to Explore Algorae’s AI-Driven Drug Discovery Platform?

Algorae Pharmaceuticals (ASX: 1AI) has secured launch partner status within the NVIDIA-accelerated Sovereign AI Infrastructure initiative, positioning its proprietary AlgoraeOS platform at the forefront of governed, AI-enabled drug discovery in healthcare and life sciences. The company’s dual-track strategy combines a growing pipeline of AI-generated drug-combination candidates with a near-term commercial revenue base through its AlgoraeRx division.

Investors seeking to understand how Algorae is applying sovereign AI infrastructure across both its discovery and commercial operations can explore the full details at the Algorae Pharmaceuticals investor centre.